Stock Fundamentals

Company Information

Company Name
Biogen Inc
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NASDAQ
ISIN: US09062X1037
CIK: 0000875045
CUSIP: 449370105
Currency: USD
Full Time Employees: 7,500
Phone: 617 679 2000
Fiscal Year End: December
IPO Date: Sep 16, 1991
Description:

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Address:

225 Binney Street, Cambridge, MA, United States, 02142

Directors & Officers

Name Title Year Born
Mr. Christopher A. Viehbacher President, CEO & Director 1961
Ms. Robin C. Kramer Executive VP & CFO 1966
Ms. Nicole Murphy Executive VP and Head of Pharmaceutical Operations & Technology 1973
Dr. Priya Singhal M.D., M.P.H. Executive VP & Head of Development 1968
Mr. Sean Godbout VP, Chief Accounting Officer & Global Corporate Controller 1974
Mr. Guy Hadari Chief Information Officer NA
Mr. Tim Power M.B.A., Ph.D. Head of Investor Relations NA
Ms. Natacha Gassenbach Chief Communication Officer & Head of Corporate Affairs NA
Mr. Adam Keeney Ph.D. Executive VP & Head of Corporate Development 1977
Dr. Ginger Gregory Ph.D. Executive VP & Chief Human Resources Officer 1968

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 12, 2026 Nicole Murphy N/A Purchase 3.00 $195.03 $585.09
Feb 09, 2026 Priya Singhal N/A Sale 2.66K $199.83 $531.55K
Feb 06, 2026 Ro Khanna N/A Sale N/A $201.18 N/A
Feb 02, 2026 Priya Singhal N/A Sale 748.00 $179.30 $134.12K
Jan 30, 2026 Gilbert Ray Cisneros, Jr. N/A Purchase N/A $179.89 N/A
Jan 29, 2026 Ro Khanna N/A Purchase N/A $176.18 N/A
Sep 02, 2025 Priya Singhal N/A Sale 517.00 $133.55 $69.05K
Aug 26, 2025 Ro Khanna N/A Purchase N/A $136.72 N/A
Jul 08, 2025 Rachid Izzar N/A Sale 2.22K $135.00 $300.11K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Vanguard Group Inc 17.45M Dec 31, 2025 11.82% $0.04 0.91%
BlackRock Inc 15.97M Mar 31, 2026 10.82% $0.05 7.85%
PRIMECAP Management Company 14.76M Mar 31, 2026 10.00% $2.13 0.00%
FMR Inc 12.81M Mar 31, 2026 8.68% $0.12 35.88%
Vanguard Capital Management, LLC 9.54M Mar 31, 2026 6.46% $0.04 0.00%
State Street Corp 7.17M Mar 31, 2026 4.86% $0.05 0.12%
Vanguard Portfolio Management, LLC 6.53M Mar 31, 2026 4.42% $0.06 0.00%
Geode Capital Management, LLC 4.34M Mar 31, 2026 2.94% $0.05 3.41%
Wellington Management Company LLP 2.96M Mar 31, 2026 2.01% $0.10 -16.60%
NORGES BANK 2.64M Dec 31, 2025 1.79% $0.05 16.55%
Morgan Stanley - Brokerage Accounts 2.17M Mar 31, 2026 1.47% $0.02 -6.63%
JPMorgan Chase & Co 2.02M Mar 31, 2026 1.37% $0.02 8.55%
AQR Capital Management LLC 1.92M Mar 31, 2026 1.30% $0.16 25.84%
Amvescap Plc. 1.75M Mar 31, 2026 1.18% $0.05 5.43%
Boston Partners Global Investors, Inc 1.70M Mar 31, 2026 1.15% $0.33 -1.19%
Northern Trust Corp 1.45M Mar 31, 2026 0.98% $0.04 0.03%
UBS Asset Mgmt Americas Inc 1.38M Mar 31, 2026 0.93% $0.05 -0.99%
Legal & General Group PLC 1.35M Mar 31, 2026 0.91% $0.06 -7.52%
T. Rowe Price Investment Management,Inc. 1.16M Mar 31, 2026 0.79% $0.15 -40.44%
Bank of America Corp 1.16M Mar 31, 2026 0.78% $0.02 2.44%

Shares Statistics

Shares Outstanding: 147.64M
Shares Float: 147.18M
% Insiders: 18.80%
% Institutions: 9,629.10%
Short % Float: 4.32%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard PRIMECAP Inv 8.36M 5.66% ▲ 0.00% Mar 31, 2026
2 Vanguard Total Stock Mkt Idx Inv 4.67M 3.17% ▲ 0.36% Apr 30, 2026
3 Fidelity Contrafund 3.94M 2.67% ▲ 20.58% Apr 30, 2026
4 Vanguard 500 Index Investor 3.81M 2.58% ▲ 1.82% Apr 30, 2026
5 Vanguard Mid Cap Index Institutional 3.18M 2.15% ▲ 0.22% Apr 30, 2026
6 Vanguard Health Care Inv 2.40M 1.63% ▼ 17.54% Mar 31, 2026
7 Vanguard Capital Opportunity Inv 2.33M 1.58% ▲ 0.00% Mar 31, 2026
8 iShares Core S&P 500 ETF 1.93M 1.31% ▲ 0.31% May 29, 2026
9 Fidelity 500 Index 1.88M 1.27% ▲ 0.35% Apr 30, 2026
10 State Street® SPDR® S&P 500® ETF 1.78M 1.20% ▲ 0.11% May 31, 2026

Valuation Metrics

Enterprise Value: $31.68B
Trailing P/E: 21.41
Forward P/E: 14.27

Financial Highlights

Market Cap: $29.40B
EBITDA: $3.54B
P/E Ratio: $21.41
PEG Ratio: $4.20
Book Value: $126.37
Earnings/Share: $9.30
Profit Margin: 13.81%
Operating Margin: 22.90%
ROA (TTM): 5.95%
ROE (TTM): 7.70%
Revenue (TTM): $9.94B
Revenue/Share (TTM): $67.71
Earnings Growth (YOY): 31.10%
Revenue Growth (YOY): 1.90%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 2.68x 0.35x 0.38x 7.63x 2.05x
2024-12-31 1.35x 0.38x 0.40x 9.95x 2.10x
2023-12-31 2.00x 0.47x 0.45x 8.49x 2.92x
2022-12-31 2.99x 0.48x 0.45x 11.72x 1.83x
2021-12-31 1.83x 0.67x 0.54x 11.01x 1.85x
2020-12-31 1.84x 0.71x 0.57x 20.64x 1.49x
2019-12-31 1.72x 0.45x 0.51x 37.58x 0.77x
2018-12-31 2.32x 0.46x 0.48x 29.35x 0.85x
2017-12-31 2.34x 0.47x 0.47x 21.31x 0.90x
2016-12-31 2.62x 0.54x 0.47x 19.81x 1.03x
2015-12-31 2.60x 0.70x 0.52x 51.21x 1.16x
2014-12-31 2.11x 0.05x 0.24x 134.66x 0.13x
2013-12-31 1.81x 0.07x 0.27x 78.86x 0.20x
2012-12-31 1.96x 0.16x 0.31x 50.37x 0.52x
2011-12-31 3.26x 0.17x 0.29x 52.26x 0.51x
2010-12-31 2.42x 0.22x 0.33x 34.60x 0.74x
2009-12-31 3.47x 0.18x 0.27x 36.19x 0.61x
2008-12-31 2.66x 0.19x 0.32x 23.34x 0.67x
2007-12-31 1.08x 0.28x 0.36x 19.25x 1.17x
2006-12-31 2.94x 0.01x 0.16x 505.19x 0.11x
2005-12-31 2.78x 0.06x 0.17x 24.47x 0.57x
2004-12-31 1.53x 0.12x 0.26x 2.30x 1.63x
2003-12-31 4.54x 0.14x 0.26x -57.28x -1.22x
2002-12-31 21.63x 0.55x 0.21x 60.31x 3.38x
2001-12-31 3.72x 0.10x 0.22x 91.10x 0.33x
2000-12-31 4.20x 0.12x 0.23x 76.18x 0.25x
1999-12-31 4.78x 0.00x 0.23x N/A 0.01x
1998-12-31 5.31x 0.01x 0.22x N/A 0.02x
1997-12-31 4.81x 0.06x 0.34x N/A 0.18x
1996-12-31 4.95x 0.01x 0.24x N/A 0.07x
1995-12-31 6.37x 0.00x 0.18x N/A 0.09x
1994-12-31 6.15x 0.00x 0.13x N/A 0.00x
1993-12-31 9.73x 0.00x 0.09x N/A 0.00x
1992-12-31 10.24x 0.00x 0.08x N/A 0.00x
1991-12-31 14.84x 0.00x 0.06x N/A 0.00x
1990-12-31 9.51x 0.00x 0.08x N/A 0.00x
1989-12-31 19.93x 0.00x 0.04x N/A 0.00x
1988-12-31 7.20x 0.00x 0.16x N/A 0.00x
1987-12-31 7.61x 0.00x 0.16x N/A 0.00x
1986-12-31 10.22x 0.00x 0.11x N/A 0.00x
1985-12-31 7.70x 0.00x 0.13x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about BIIB.US!